SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ — Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002…